Welcome to our dedicated page for GCAND SEC filings (Ticker: GCAND), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Our SEC filing database is enhanced with expert analysis from Rhea-AI, providing insights into the potential impact of each filing on GCAND's stock performance. Each filing includes a concise AI-generated summary, sentiment and impact scores, and end-of-day stock performance data showing the actual market reaction. Navigate easily through different filing types including 10-K annual reports, 10-Q quarterly reports, 8-K current reports, proxy statements (DEF 14A), and Form 4 insider trading disclosures.
Designed for fundamental investors and regulatory compliance professionals, our page simplifies access to critical SEC filings. By combining real-time EDGAR feed updates, Rhea-AI's analytical insights, and historical stock performance data, we provide comprehensive visibility into GCAND's regulatory disclosures and financial reporting.
The Greater Cannabis Company, Inc. reported a full-year 2025 net loss of $331,612 on $0 in revenue, similar to 2024. Operating expenses rose to $183,005 from $156,276, reflecting ongoing development activity without commercial sales.
Cash declined to $815 at December 31, 2025, against current liabilities of $742,464, and the auditor highlighted substantial doubt about the company’s ability to continue as a going concern. Management is focused on a licensed cannabinoid therapy from Shaare Zedek Scientific and plans a Phase II clinical trial once specialized API is sourced and additional funding is raised. During 2025 the company completed a 1-for-1,500 reverse stock split and created Series B Preferred Shares, giving its CEO majority voting control while common shares outstanding reached 944,935 as of March 16, 2026.